Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 8/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.66 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.66 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.66 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | PDE5A | O76074 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974545 | 0.90 | NPY5R (0.66) | LMNACYP1A2CYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL3123061 | 0.83 | MEN1 (0.67) | LMNAALDH1A1POLBKMT2AMEN1 | |
| SCHEMBL16404470 | 0.82 | ABCG2 (0.61) | KDM4ESMN1; SMN2PDE5AKMT2AMEN1 | |
| SCHEMBL3121675 | 0.81 | ALDH1A1 (0.66) | LMNACYP1A2CYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL2258103 | 0.80 | KDM1A (0.71) | LMNACYP1A2CYP3A4KDM4EHPGD | |
| SCHEMBL3108501 | 0.80 | NPY5R (0.72) | LMNAALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL3110763 | 0.80 | MAPT (0.54) | LMNACYP1A2CYP3A4ALDH1A1KDM4E | |
| SCHEMBL2257123 | 0.80 | KDM1A (0.64) | LMNAALDH1A1TGFBR1MAPK14KDM4E | |
| SCHEMBL14262810 | 0.80 | TGFBR1 (0.61) | LMNACYP1A2CYP3A4ALDH1A1HSD17B10 | |
| SCHEMBL414358 | 0.80 | CYP1A2 (1.00) | LMNACYP1A2CYP3A4ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | MYREXIS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8309562-B2 | Compounds and therapeutical use thereof | MYREXIS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| CN-1984660-B | 4-arylamino-quinazolines as activators of aspartic acid specificity cysteine protease and inducers of apoptosis | MYRIAD GENETICS INC | 2010-12-15 | — | — | CN | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| CN-1984660-A | 4-arylamino-quinazolines as activators of aspartic acid specificity cysteine protease and inducers of apoptosis | MYRIAD GENETICS INC (US) | 2007-06-20 | — | — | CN | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208044-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885CYP1A2 2087/4885CYP3A4 975/4885 |
| US-20130029942-A1 | COMPOUNDS AND THERAPEUTICAL USES THEREOF | BAD, CASP3, BAX | LMNA 940/4885CYP1A2 2066/4885CYP3A4 1067/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885CYP1A2 2087/4885CYP3A4 975/4885 |
| US-20170050937-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885CYP1A2 2087/4885CYP3A4 975/4885 |
| US-20070244114-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | LMNA 1197/4885CYP1A2 2087/4885CYP3A4 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.